Transcriptional Regulation of the Yeast GMP Synthesis Pathway by Its End Products*

Mafalda Escobar-Henriques and Bertrand Daignan-FornierDagger

From the Institut de Biochimie et Génétique Cellulaires, CNRS UMR 5095, 1 Rue Camille Saint-Saëns, F-33077 Bordeaux Cedex, France

Received for publication, August 30, 2000, and in revised form, October 12, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

AMP and GMP are synthesized from IMP by specific conserved pathways. In yeast, whereas IMP and AMP synthesis are coregulated, we found that the GMP synthesis pathway is specifically regulated. Transcription of the IMD genes, encoding the yeast homologs of IMP dehydrogenase, was repressed by extracellular guanine. Only this first step of GDP synthesis pathway is regulated, since the latter steps, encoded by the GUA1 and GUK1 genes, are guanine-insensitive. Use of mutants affecting GDP metabolism revealed that guanine had to be transformed into GDP to allow repression of the IMD genes. IMD gene transcription was also strongly activated by mycophenolic acid (MPA), a specific inhibitor of IMP dehydrogenase activity. Serial deletions of the IMD2 gene promoter revealed the presence of a negative cis-element, required for guanine regulation. Point mutations in this guanine response element strongly enhanced IMD2 expression, also making it insensitive to guanine and MPA. From these data, we propose that the guanine response element sequence mediates a repression process, which is enhanced by guanine addition, through GDP or a GDP derivative, and abolished in the presence of MPA.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Purine nucleotides are involved in many important cellular processes, and therefore a balanced synthesis of AMP and GMP is required. Cells can synthesize purine nucleotides through the de novo pathway, a 10-step pathway that produces IMP, which in turn serves as the common precursor for AMP and GMP nucleotide biosynthesis (Fig. 1). In yeast, the regulation of the ADE genes involved in AMP biosynthesis has been characterized (1, 2). Expression of the ADE genes is repressed by extracellular adenine and activated by the transcription factors Bas1p and Bas2p. However, in Saccharomyces cerevisiae, GMP biosynthesis regulation has not received much attention and is therefore poorly understood. IMP dehydrogenase (IMPDH),1 catalyzing the first step of de novo guanine nucleotide synthesis, has a key role on growth of many cell types, including lymphocytes and rapidly proliferating cells (see Ref. 3 for a recent review).



View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic representation of purine nucleotides de novo and salvage pathways. Solid lines represent the plasma membrane. The following abbreviations are used: Ade, adenine; ext, extracellular medium; Gua, guanine; Hyp, hypoxanthine; int, intracellular compartment; PRPP, 5-phosphoribosyl-1-pyrophosphate. Gene names are italicized and encode the following enzymatic activities: AAH1, adenine deaminase; APT1, adenine phosphoribosyltransferase; FCY2, purine cytosine permease; GUA1, guanosine-5'-monophosphate synthetase; GUK1, guanosine-5'-monophosphate kinase; HPT1, hypoxanthine-guanine phosphoribosyltransferase; IMDs, inosine-5'-monophosphate dehydrogenases; RNR, ribonucleotide reductase; YNK1, nucleoside-5'-diphosphate kinase.

GMP synthesis and its regulation appear to play a crucial role in cell proliferation, since an increased level of IMPDH activity has been observed in rapidly proliferating cells (4), including human leukemic cell lines (6-9), solid tumor tissues (10), and B- and T-activated lymphocytes (5). Indeed, substances blocking IMPDH activity, such as mycophenolic acid (MPA), act as immunosuppressive drugs and are used to prevent allograft rejection (11-16; see Ref. 17 for recent reviews). Moreover, it was recently shown that a low level of IMPDH activity is necessary for p53-dependent growth suppression. Indeed, constitutive expression of IMPDH abolishes p53-dependent growth suppression (18), although the exact mechanism is not known.

To assess the molecular mechanisms governing guanylic nucleotide synthesis, we have proceeded to study the regulation of GTP synthesis in Saccharomyces cerevisiae. In this yeast, GMP synthetase, GMP kinase, and NDP kinase, required for catalysis of the latter steps of guanylic nucleotide biosynthesis, are encoded by the GUA1, GUK1, and YNK1 genes, respectively (Fig. 1) (19-21). IMPDH, catalyzing the first committed step in guanylic nucleotide biosynthesis, has been isolated from a variety of eukaryotic and prokaryotic sources and exhibits a high level of amino acid conservation (22-27). Molecular mass, kinetic parameters, and reaction mechanism are also similar, demonstrating a high degree of conservation among species (28-30). By using these features and the complete sequencing of the S. cerevisiae genome, we have identified four yeast homologs for IMPDHs, YAR073w, YHR216w, YLR432w, and YML056c, that we named IMD1, IMD2, IMD3, and IMD4 genes, respectively. These genes encode proteins with more than 80% amino acid identity to each other and that share about 60% amino acid residues with human IMPDHs type I and type II.

In this paper we have studied the regulation of the yeast GMP synthesis genes, and we found that GMP synthesis is differently regulated from IMP and AMP synthesis. We show that the IMD genes transcript levels are impaired by guanine but not by adenine. IMDs transcriptional expression is strongly activated by MPA. Mutational analysis of the sequences upstream of IMD2 ATG allowed us to identify a cis-element (TATAAATA), named guanine response element (GRE), affecting guanine regulation; several trans-mutations affecting regulation of IMDs are also presented. We propose that IMD2 regulation by MPA and guanine takes place through the cis-acting GRE, in response to intracellular concentrations of GDP or a derivative of GDP.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Yeast Media-- SD is 2% glucose, 0.17% nitrogen base, and 0.5% ammonium sulfate. Adenine or guanine were optionally added to a final concentration of 0.15 and 0.13 mM, respectively. Hydroxyurea (HU) was used at a concentration of 240 mM. SD casa is SD supplemented with 0.2% casamino acids (Difco).

Yeast Strains-- Two sets of isogenic strains were used as follows: Y350 (MATa; ura3-52; leu2-3, 112; lys2Delta 201), 216 (MATa; ura3-52; leu2-3, 112; lys2Delta 201; hpt1-2), 220 (MATa; ura3-52; leu2-3, 112; lys2Delta 201, guk1-3), Y349 (MATalpha ; ura3-52; leu2-3, 112; lys2Delta 201; his3Delta 200), 119 (MATalpha ; ura3-52; leu2-3, 112; lys2Delta 201; his3Delta 200; fcy2-1); and D451-3 (MATa; leu2-3, 112; ura3-52), D451-3Delta ynk1 (MATa; leu2-3, 112; ynk1::URA3).

Plasmids-- The lacZ fusions were constructed in the vectors described by Myers and coworkers (31). Except for P777, all of them are URA3 vectors. The IMD1-lacZ fusion (P677) was constructed as follows: a 389-bp KpnI-BglII restriction fragment, starting 357 bp upstream from the ATG initiation codon, was cloned in YEp353 linearized with BamHI and KpnI. For IMD2-lacZ (P354), a 2321-bp BamHI-HindIII fragment from P260 (a plasmid carrying the IMD2 gene in YEp13), starting 1186 bp upstream from the ATG initiation codon, was cloned in YEp356 linearized with BamHI and HindIII. A IMD2-lacZ fusion (P777) was also constructed in a plasmid carrying the LEU2 selection gene, by cloning the BamHI-HindIII fragment of P354 in the YEp366 vector, described by Myers and coworkers (31). The IMD3-lacZ fusion was constructed as follows: a 588-bp EcoRI-EcoRV restriction fragment, starting 555 bp upstream from the ATG initiation codon, was cloned in YEp356R linearized with SmaI and EcoRI. For IMD4-lacZ, a 2573-bp HindIII-EcoRI restriction fragment, starting 668 bp upstream from the ATG initiation codon, was cloned in YEp356R linearized with HindIII and EcoRI. The GUA1-lacZ fusion was constructed by inserting the BamHI-BglII restriction fragment from pFL44/T1-BE (19) in YEp358R linearized with BamHI. Construction of GUK1-lacZ was done as follows: a 1657-bp EcoRI fragment starting 1486 bp upstream from the ATG initiation codon was cloned in YEp356R linearized with EcoRI. lacZ fusion plasmids used for characterization of the IMD2 gene promoter were constructed as follows. All the desired IMD2 fragments were obtained by polymerase chain reaction (PCR) using the appropriate promoter-coding strand synthetic oligonucleotide and the noncoding strand IMP22 synthetic oligonucleotide. The resulting PCR fragments were digested with BamHI-HindIII and cloned at the BamHI-HindIII sites of the YEp356 vector (31). The plasmids containing 442, 355, 311, 287, 263, 234, 197, 159, or 108 bp of the IMD2 promoter and 1135 bp of its coding sequence were named P853, P855, P892, P895, P857, P1527, P1528, P860 and P890, respectively, and were obtained with the oligonucleotide IMP2-442, IMP2-355, IMP2-311, IMP2-287, IMP2-263, IMP2-234, IMP2-197, IMP2-159, or IMP2-108, respectively. The plasmids containing triple CCC mutations in the -311 to -287 region of the IMD2 promoter, named P909, P963, P911, P913, P915, P917, P919, P921, and P923, were obtained with the oligonucleotide IMP2-C309, IMP2-308, IMP2-C300, IMP2-C297, IMP2-C294, IMP2-C291, or IMP2-C288, respectively. The plasmids containing a single C mutation in the -308 to -301 region of the IMD2 promoter, named P1369, P1370, P1372, P1326, P1328, P1330, P1332, and P1334, were obtained with the oligonucleotide IMP2-C1, IMP2-C2, IMP2-C3, IMP2-C4, IMP2-C5, IMP2-C6, IMP2-C7, or IMP2-C8, respectively. The oligonucleotides used to PCR amplify the IMD2 fragments from the S288C genomic DNA template were as follows: IMD2 promoter, coding strand, IMP2-442, 5'-CGGGATCCCGTGTCTGTTCTCTACA-3'; IMP2-355, 5'-CGGGATCCCGAAGAAAGCGGAAAAATAA-3'; IMP2-311, 5'-CGGGATCCAAGTATAAATAGTGAAGAC-3'; IMP2-287, 5'-CGGGATCCCATTTGATATTTGGTA-3'; IMP2-263, 5'-CGGGATCCCGGCTGGAAGTTTTTTGC-3'; IMP2-232, 5'-CGGGATCCGGAGAATCTTGGTGGCTT-3'; IMP2-197, 5'-CGGGATCCTTATACATTTTACCTAGT-3'; IMP2-159, 5'-CGGGATCCCGTATTCTATTCTATTCCT-3'; IMP2-108, 5'-CGGGATCCCAATTTCAATAATACTT-3'; IMP2-C309, 5'-CGGGATCCGTATAAATAGTGAAGACT-3'; IMP2-308, 5'-CGGGATCCCTATAAATAGTGAAGACT-3'; IMP2-C306, 5'-CGGGATCCAACCCTAAATAGTGAAGACTTTTTC-3'; IMP2-C303, 5'-CGGGATCCAAGTACCCATAGTGAAGACTTTTTCC-3'; IMP2-C300, 5'-CGGGATCCAAGTATAACCCGTGAAGACTTTTTCCAT-3'; IMP2-C297, 5'-CGGGATCCAAGTATAAATACCCAAGACTTTTTCCATTTG-3'; IMP2-C294, 5'-CGGGATCCAAGTATAAATAGTGCCCACTTTTTCCATTTGATA-3'; IMP2-C291, 5'-CGGGATCCAAGTATAAATAGTGAAGCCCTTTTCCATTTGATATTTG-3'; IMP2-C288,5'-CGGGATCCAAGTATAAATAGTGAAGACTCCCTCCATTTGATATTTGGT-3'; IMP2-C1, 5'-CGGGATCCAAGCATAAATAGTGAAGACT-3'; IMP2-C2, 5'-CGGGATCCAAGTCTAAATAGTGAAGACT-3'; IMP2-C3, 5'-CGGGATCCAAGTACAAATAGTGAAGACT-3'; IMP2-C4, 5'-CGGGATCCAAGTATCAATAGTGAAGACT-3'; IMP2-C5, 5'-CGGGATCCAAGTATACATAGTGAAGACT-3'; IMP2-C6, 5'-CGGGATCCAAGTATAACTAGTGAAGACT-3'; IMP2-C7, 5'-CGGGATCCAAGTATAAACAGTGAAGACT-3'; IMP2-C8, 5'-CGGGATCCAAGTATAAATCGTGAAGACT-3'; and for the IMD2 open reading frame, noncoding strand, IMP22, 5'-TCCCCCGGGCCCAAATACCGTA-3'.

beta -Galactosidase Assays-- For beta -galactosidase assays, cells were grown overnight in SD casa and then diluted in the same medium supplemented or not with adenine, guanine, HU, or MPA. After 6 h at 30 °C (or 12 h for HU assays), the beta -galactosidase assays were performed on these exponentially growing cells. Cells were made permeable by the method of Kippert (32) with N-lauroyl sarcosine. Units of beta -galactosidase activity were calculated by the Equation 1,


<UP>Units </UP>(<UP>Miller units</UP>)=<FR><NU>1000×A<SUB>420(<UP>mix</UP>)</SUB></NU><DE>A<SUB>600(<UP>culture</UP>)</SUB>×V<SUB><UP>culture</UP></SUB>(<UP>ml</UP>)×t<SUB><UP>assay</UP></SUB>(<UP>min</UP>)</DE></FR> (Eq. 1)
In each experiment, at least two independent beta -galactosidase assays were performed, and each assay was done on four independent transformants. Inter-assay variation was <20%. Growth inhibition by HU or mycophenolic acid drugs is calculated on the average A600 of the four independent transformants, by Equation 2,
% <UP>inhibition</UP>=<FR><NU>A<SUB>600(<UP>without drug</UP>)</SUB>−A<SUB>600(<UP>with drug</UP>)</SUB></NU><DE>A<SUB>600(<UP>without drug</UP>)</SUB></DE></FR>×100 (Eq. 2)

Northern Blots-- Yeast strains Y350 and 220 were grown in SD casa, supplemented or not with 0.13 mM guanine or 0.03 µg/ml mycophenolic acid, to an A600 = 0.5. After centrifugation, glass beads were added to the cell pellet, and total RNA was isolated using either the CLONsep Total RNA Isolation Kit (CLONTECH) (for experiments in Fig. 2 and 7) or the TRI Reagent RNA/DNA/PROTEIN Isolation Reagent (EUROMEDEX) (for experiments in Fig. 8). RNA blots were prepared as described previously (2) and probed with a labeled PCR fragment, specific for the IMD2 gene. After autoradiography, bound probes were removed from the membranes and then probed again with the ACT1 gene, as described previously (2). The oligonucleotides used to PCR-amplify the IMD2 probe from the S288C genomic DNA template are as follows: IMP2coli, 5'-TTTTTGCATGCCGCCATTAGAGACTAC-3', and IMP22, 5'-TCCCCCGGGCCCAAATACCGTA-3'. Radiolabeling of the probes was carried out using the random-priming procedure (Kit Prime-a-Gene labeling system, Promega).

IMD2 mRNA 5'-Mapping-- The transcription start for IMD2 was determined as follows: 10 µg of total RNAs were treated with DNase and RNasin for 1 h at 37 °C, followed by a phenol/chloroform extraction and RNA precipitation. The 5' extremity of the IMD2 transcript was then mapped with the Roche Molecular Biochemicals 5'/3'-rapid amplification of cDNA ends kit using the following primers: SP1-5'-CCCAAGCTTAGGCTAACTTCAGAGG-3', SP2-5'-CCCAAGCTTGCAAAATCGACTAAACCT-3', and SP3-5'-CCCAAGCCCCCATTGCTTTTGCTACT-3'.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression of IMD Genes Is Repressed by Guanine but Not by Adenine-- To investigate whether GDP biosynthesis genes are coregulated with the AMP pathway genes, i.e. repressed by external addition of adenine, fusions between the GDP biosynthesis genes and the lacZ reporter gene were constructed. The beta -galactosidase activity of these fusions was measured in the presence or absence of adenine. As shown in Fig. 2, expression of all the tested lacZ fusions was not affected by adenine addition. Expression of the IMD1-lacZ fusion was hardly detectable. In fact, IMD1 is thought to be a silent gene, since it carries a frameshift in its coding sequence, and its transcript was not detectable (33).



View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of adenine and guanine on expression of GDP biosynthesis genes. A, Y350 (wild-type) was transformed with the indicated lacZ fusion plasmids and grown for 6 h in SD casa medium supplemented or not with 0.15 mM adenine or 0.13 mM guanine. Cells were harvested and assayed for beta -galactosidase (beta Gal) activity, as described under "Experimental Procedures." B, total RNAs from the Y350 wild-type strain, grown for 6 h in SD casa with or without guanine (0.13 mM), were analyzed by Northern blotting using probes for the gene IMD2 and the control gene ACT1.

Expression of the lacZ fusion genes was also tested in the presence of external guanine. Guanine clearly impaired expression of the IMD2, -3, and -4 lacZ fusions, whereas it did not affect expression of GUA1-lacZ and GUK1-lacZ fusions (Fig. 2A). Thus, only the first step of GDP synthesis appeared to be regulated by guanine. Expression of IMD2 was also monitored in the presence or absence of guanine by Northern blot analysis. Results presented in Fig. 2B and quantification of the blots (data not shown) revealed that the IMD2 transcript was 3-fold less abundant in the presence of guanine. In this experiment, cross-hybridization with IMD3 and IMD4 transcripts cannot be totally excluded, since the IMD2 probe used is 85 and 87% identical to IMD3 and IMD4, and coding sequences of these three genes have approximately the same size. However, if this happens, it further suggests that IMDs are coregulated, in agreement with beta -galactosidase results. Because IMD2 is the most repressed gene, we focused on the regulation of this member of the IMPDH family.

Guanine Must Be Metabolized to GDP to Repress IMD2 Expression-- Since IMD2 was down-regulated in the presence of extracellular guanine, we investigated the signaling pathway controlling guanine-responsive genes. A IMD2-lacZ fusion was studied in several yeast genetic backgrounds in which guanine utilization is impaired (Fig. 1). The importance of guanine uptake was first analyzed by assaying guanine repression in a strain mutated at the fcy2 locus, encoding purine-cytosine permease. Data presented in Table I show that the fcy2 mutant failed to repress the IMD2 gene expression in response to guanine (compare Y349 to 119), indicating that guanine uptake is strictly required for repression. Once inside the cell, guanine can be metabolized into GMP by the hypoxanthine-guanine phosphoribosyltransferase enzyme, encoded by the HPT1 gene (Fig. 1) (34). Analysis of the IMD2-lacZ fusion expression in a strain mutated at the HPT1 locus (35) showed that the hypoxanthine phosphoribosyltransferase enzyme is necessary to transduce the repression signal (Table I, compare Y350 to 216). GMP can then be phosphorylated to GDP. This step is catalyzed by GMP kinase, encoded by the GUK1 essential gene. Expression of the IMD2-lacZ fusion was assayed in the guk1-3 mutant strain strongly impaired for the GMP kinase activity (36). Results presented in Table I clearly show that regulation by guanine of the IMD2-lacZ gene is completely abolished in this strain (compare Y350 to 220). Thus, guanine must be transformed into GDP to repress IMD genes expression.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of mutations impairing guanine utilization on repression of IMD2-lacZ fusion by guanine
The indicated strains, transformed with IMD2-lacZ, were grown for 6 h in SD medium supplemented with casamino acids for derepressing conditions (DR) or in the same medium containing 0.13 mM guanine, for repressing conditions (R). beta -Galactosidase (beta -Gal) activities were determined as described under "Experimental Procedures." DR/R is the ratio of the values measured under derepressing versus repressing conditions (repression ratio). wt stands for wild-type.

Further metabolism of GDP involves its reduction to dGDP by ribonucleotide reductase or its phosphorylation to GTP by nucleotide diphosphate kinase. The importance of deoxyribonucleotides in this transduction pathway can be assessed with HU, a drug that specifically inhibits ribonucleotide reductase activity (37, 38). In the absence of HU, guanine addition led to a 5-fold reduction of IMD2-lacZ expression (data not shown). In the presence of 240 mM HU, a dose that resulted in 96% of growth inhibition (see "Experimental Procedures"), guanine provoked a comparable (6-fold) reduction in IMD2-lacZ fusion expression (data not shown). Thus, we found that HU did not affect repression by guanine, even at doses that strongly inhibit cell growth. This result clearly shows that dGDP does not participate in the transduction pathway of guanine repression. Expression of the IMD2-lacZ fusion was assayed in a strain deleted for the nucleotide diphosphate kinase-encoding gene, YNK1, and in an isogenic wild-type strain (21). In the absence of guanine, activity of IMD2-lacZ in the YNK1 and ynk1 strains was 241 and 234 beta -galactosidase units, respectively. Guanine addition decreased IMD2-lacZ expression to 18 and 30 beta -galactosidase units, in the YNK1 and ynk1 strains, respectively. Thus, IMD2 repression by guanine was not severely affected by ynk1 disruption, meaning that the nucleotide diphosphate kinase encoded by the YNK1 gene is not necessary for the transduction of the guanine repression signal. Altogether, these results indicate that the signal molecule responsible for IMD2 repression by guanine could be either GDP itself or a yet unidentified derivative of GDP.

Expression of the IMD2 Gene Is Activated by the Immunosuppressive Drug MPA-- We then examined the effect of MPA, a potent and specific inhibitor of eukaryotic IMPDHs and an immunosuppressive drug (see Introduction) on the expression of the IMD2 gene. We reasoned that since GDP or a derivative of GDP represses IMD2 gene expression, MPA inhibition of XMP synthesis should starve the cells for guanine nucleotides, which should result in enhanced expression of IMD2. A range of MPA concentrations was tested for both growth inhibition and expression of the IMD2-lacZ fusion. Results presented in Fig. 3 show that MPA inhibited growth in a dose-dependent manner. In parallel, MPA activated the IMD2-lacZ fusion gene expression, and this response was maximal between 0.03 and 0.3 µg/ml MPA. Addition of guanine completely reversed both MPA toxicity (data not shown) and its effect on IMD2-lacZ expression (Fig. 3), thus confirming the high specificity of this drug. A concentration of 0.03 µg/ml MPA fully activated IMD2-lacZ fusion and only slightly affected growth; therefore, this drug concentration was chosen for further experiments.



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of MPA, a drug inhibiting IMPDH, on IMD2-lacZ expression. Y350 (wt) strain, transformed with IMD2-lacZ, was grown for 6 h in the presence of increasing amounts of MPA, in SD medium supplemented with casamino acids for derepressing conditions or in the same medium containing 0.13 mM guanine, for repressing conditions. beta -Galactosidase activities were determined as described under "Experimental Procedures." Vertical bars represent beta -galactosidase (beta Gal) expression under derepression and repression conditions in the presence of increasing amounts of the growth inhibitor MPA. The growth inhibition percentage, shown by the solid line, is calculated as indicated under "Experimental Procedures."

Identification of a GRE in the IMD2 Promoter-- As a first step toward identification of promoter cis-elements responsible for IMD2 regulation, we mapped the IMD2 transcription start. 5'-Rapid amplification of cDNA ends mapping was done on RNA extracted from cells grown in the presence of either guanine or MPA. In both cases transcription started at the C nucleotide 107 bp upstream the ATG. The IMD2-lacZ plasmid used in the previous experiments contained 853 bp of 5'-flanking sequence. To map the 5'-boundary of the regulatory region of the IMD2 gene, sequential deletions of the 5'-flanking sequence of IMD2-lacZ were constructed, from 853 to 108 bp upstream from the IMD2 ATG. Expression and regulation by guanine of these constructs were assayed in a wild-type strain (Y350). IMD2-lacZ fusion genes containing 442, 355, and 311 bp upstream of the start codon (Fig. 4, plasmids P853, P855, and P892) were repressed by guanine, as the control IMD2-lacZ plasmid (Fig. 4, P354). In contrast, an IMD2-lacZ fusion gene containing 287 bp of the 5'-flanking sequence (Fig. 4, P895) was insensitive to guanine and was expressed at a much higher level than the control fusion. A similar derepression profile was found for IMD2-lacZ fusion genes containing 263, 234, 197, 159, or 108 bp of the 5'-flanking sequence (Fig. 4, P857, P1527, P1528, P860, and P890), although they were less expressed than the -287 fusion gene. These results suggested the presence of a cis-negative GRE whose 5'-boundary would be between -311 and -287 bp. Positive regulatory cis-elements might also be present between -287 and -108 bp.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of deletions in IMD2 promoter on guanine repression of IMD2-lacZ expression. Y350 (wt) strain was transformed with the IMD2-lacZ indicated plasmids and grown for 6 h in SD medium supplemented with casamino acids, for derepressing conditions (DR) or in the same medium containing 0.13 mM guanine, for repressing conditions (R). beta -Galactosidase activities were determined as described under "Experimental Procedures." DR/R is the ratio of the values measured under derepressing versus repressing conditions (repression ratio).

To investigate more precisely the importance of the region between -311 and -287 bp in the IMD2 promoter, this region was submitted to site-directed mutagenesis. Triplet CCC mutations were created in the 24 nucleotides spanning the interval -311 to -287. Constructs carrying the clustered mutations were assayed for their effects on beta -galactosidase expression under both guanine-repressing and -derepressing conditions. The results shown in Fig. 5 indicate that the CCC substitutions in clusters GTA, TAA, and ATA (plasmids P911, P913, and P915) abolished guanine regulation and enhanced expression of these fusions, as compared with the parental construct. On the other hand, all the other clustered substitutions had no effect, neither on guanine regulation nor on the expression levels of the IMD2-lacZ gene fusion. Comparison of data obtained with plasmids P909 and P963 show that the G to C mutation of the GTA cluster does not affect guanine regulation of the IMD2 gene. In summary, results from this cluster mutations experiment demonstrate that changing the octanucleotide TATAAATA into CCTAAATA, TACCCATA, or TATAACCC completely prevents guanine regulation of the IMD2 gene. To identify more precisely the critical nucleotides contained therein, each nucleotide of the TATAAATA box was mutated to a C. The lacZ fusion constructs, each containing a C substitution in the octanucleotide and 311 bp of the 5'-flanking sequence of the IMD2 gene, were tested in guanine-repressing and -derepressing conditions. As shown in Fig. 6, each single mutation introduced led to a guanine-insensitive derepression of the IMD2-lacZ expression, thus revealing that all eight nucleotides of the TATAAATA sequence are required for transcriptional regulation of the IMD2 gene. The TATAAATA box was named GRE. To ensure that this regulation occurs at the transcriptional level, we measured the expression of a wild-type GRE and a mutant GRE IMD2-lacZ fusion in a wild-type strain grown in the presence or absence of external guanine by Northern blot analysis. We first confirmed that regulation by guanine was maintained for the -311 IMD2-lacZ fusion (Fig. 7). In contrast, an IMD2-lacZ fusion gene containing a mutant sequence in the TATAAATA element was expressed at a much higher level, in a guanine-insensitive manner (Fig. 7). These results confirm that guanine regulation of IMD2 takes place at the transcriptional level, and only in the presence of a functional GRE.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 5.   Triple mutation scanning of -311 to -287 region of IMD2 promoter. Y350 (wt) strain was transformed with the IMD2-lacZ plasmids with the indicated IMD2 promoter sequence in the region between -311 and -287 bp upstream from the ATG. Transformants were grown for 6 h in SD medium supplemented with casamino acids for derepressing conditions (DR) or in the same medium containing 0.13 mM guanine for repressing conditions (R). beta -Galactosidase activities were determined as described under "Experimental Procedures." DR/R is the ratio of the values measured under derepressing versus repressing conditions (repression ratio). In the fusion constructions, underlined nucleotides show the CCC mutations introduced in the wild-type sequence.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   Single mutation scanning of -308 to -301 region of IMD2 promoter. Y350 (wt) strain was transformed with the IMD2-lacZ plasmids with the indicated mutations in the TATAAATA box of the IMD2 promoter sequence. Transformants were grown for 6 h in SD medium supplemented with casamino acids for derepressing conditions (DR) or in the same medium containing 0.13 mM guanine, for repressing conditions (R). beta -Galactosidase activities were determined as described under "Experimental Procedures." DR/R is the ratio of the values measured under derepressing versus repressing conditions (repression ratio). In the fusion constructions, underlined nucleotides show the C mutations introduced in the wild-type sequence.



View larger version (48K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of mutations in the GRE on IMD2-lacZ mRNA levels. Y350 (wt) strain was transformed either with plasmid P892, containing the GRE, or with plasmid P913, with a mutant (mut) GRE. Transformants were grown for 6 h in SD medium supplemented with casamino acids or in the same medium containing 0.13 mM guanine. Cells were harvested, and total RNAs were extracted and analyzed by Northern blot using probes for the IMD2 gene or the control gene ACT1.

MPA and Guanine Signals for IMD2 Regulation Are Transduced through the Same Pathway-- IMD genes are activated by MPA and repressed by guanine. To find out whether these regulations are transduced through the same pathway, IMD2 regulation by MPA was analyzed in hpt1 and guk1 mutant strains, deficient for transduction of the guanine repression signal. Results presented in Table II and Fig. 8 confirmed that in a wild-type strain, MPA addition enhanced IMD2 expression levels. This effect was reversed by guanine addition, which decreased IMD2 expression level (Fig. 8 and Table II, line 1). In hpt1 or guk1 mutants, guanine addition was unable to repress IMD2 expression or to reverse MPA activation effect (Fig. 8 and Table II, line 1). We conclude that MPA reversion and guanine repression act through the same pathway. In this hypothesis, a mutation of the GRE box should also disable MPA regulation of the IMD2 gene. This was tested by monitoring the effect of MPA on the regulation of an IMD2-lacZ fusion carrying a mutant GRE. Results show that this fusion was expressed at a constant high level, regardless of guanine or MPA presence (Table II, line 2), meaning that IMD2 regulation by guanine or MPA is possible only in presence of the wild-type GRE box. This same fusion, in a hpt1 or guk1 mutant, behaved as in the wild-type strain, making IMD2 insensitive to guanine or MPA addition (Table II, lines 4 and 6).


                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of MPA and guanine on expression of wild-type or GRE mutant IMD2-lacZ fusion in various genetic backgrounds
The indicated strains were transformed with plasmids carrying either wild-type or GRE mutant IMD2-lacZ. Transformants were grown for 6 h in SD medium supplemented with casamino acids or in the same medium containing either 0.03 µg/ml mycophenolic acid or 0.13 mM guanine or both supplements. beta -Galactosidase (beta -Gal) activities were determined as described under "Experimental Procedures." (SD + MPA)/SD is the ratio of the values measured in the presence or absence of mycophenolic acid, respectively. wt and mut stand for wild-type and mutant, respectively.



View larger version (46K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of MPA and guanine on expression of IMD2 transcripts in wild-type and guk1-3 backgrounds. Y350 (wt) or 220 (guk1) strains were grown for 6 h in SD medium supplemented with casamino acids and uracil or in the same medium containing either 0.03 µg/ml mycophenolic acid or 0.13 mM guanine or both supplements. Cells were harvested, and total RNAs were extracted and analyzed by Northern blot using probes for the IMD2 gene or the control gene ACT1.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this report, we show that the IMD genes, encoding the S. cerevisiae homologs of IMPDH, are transcriptionally repressed by guanine, which has to be metabolized into GDP or a derivative of GDP to exert its regulatory role. Expression of IMD2 is highly enhanced in the presence of MPA. A cis-negative element, necessary to both guanine and MPA regulation, was found in the IMD2 gene promoter. A simple explanation could be that in response to guanylic nucleotides levels, a repressor could bind to the IMD2 promoter and regulate its transcription. A model for yeast regulation of the guanylic nucleotide synthesis genes is presented in Fig. 9.



View larger version (9K):
[in this window]
[in a new window]
 
Fig. 9.   Model for IMD2 regulation by MPA and guanine. The following abbreviations are used: ext, extracellular medium; int, intracellular compartment. Gene names are italicized and encode the following enzymatic activities: FCY2, purine cytosine permease (PCP); GUA1, guanosine-5'-monophosphate synthetase (GMPS); GUK1, guanosine-5'-monophosphate kinase (GMPK); HPT1, hypoxanthine-guanine phosphoribosyltransferase (HGPRT).

Specific Regulation of the Guanylic Nucleotide Pathway by Its End Product-- We showed that expression of the GDP pathway genes is unaffected by adenine; they are also unaffected by bas1 or bas2 mutations,2 i.e. the signal and transcription factors involved in regulation of IMP and AMP synthesis pathways (1, 2). These results establish that AMP and GMP synthesis are differentially regulated in S. cerevisiae.

Mechanisms of purine biosynthesis regulation have been elucidated in two bacteria, Escherichia coli and Bacillus subtilis. In E. coli, all the genes for AMP and GMP synthesis are repressed by the PurR repressor in the presence of the corepressors hypoxanthine and/or guanine (39, 40). In B. subtilis, synthesis of AMP and GMP is repressed independently by adenine and guanine nucleotides, whereas adenine nucleotides regulate transcription initiation (via the PurR repressor) (41), and guanine nucleotides regulate transcription termination by an anti-termination mechanism (42). Therefore, in these bacteria, regulation of both AMP and GMP biosynthesis pathway genes respond to AMP and GMP precursors, either through a common transcription factor as in E. coli or through independent mechanisms as in B. subtilis. The situation is clearly different in yeast where AMP synthesis genes is poorly repressed by guanine (35) and where GMP synthesis genes is not affected by adenine (this study). This differential regulation could be a general feature for eukaryotic organisms since it has been shown that expression of human IMPDH is repressed in the presence of guanosine but not adenosine (43).

Negative Regulation of IMPDH Synthesis by Guanylic Nucleotide Levels Is Conserved among Eukaryotes-- Extracellular guanine led to a 3-7-fold decrease of IMD2 transcription, depending on the experiment. The reasons for such variations of the repression factor, which occurred both with Northern blot and beta -galactosidase experiments, are unclear. In the fcy2, hpt1, or guk1 mutant strains, guanine failed to repress the IMD genes, indicating that levels of GDP or a GDP derivative negatively regulate IMD gene expression. Deletion of the YNK1 gene, encoding NDP kinase, did not affect guanine repression of IMD genes. Nevertheless, GTP cannot be totally excluded from the guanine signaling pathway, since the ynk1 disrupted strain retained 10% of GDP to GTP conversion capacity, when compared with wild-type cells (21). Inhibition of dNDPs biosynthesis by a severely growth-inhibiting dose of hydroxyurea did not affect guanine regulation of IMD2 gene. Therefore, whereas guanylic ribonucleotide levels regulate IMDs expression, guanylic deoxyribonucleotides apparently do not participate in the guanine repression transduction pathway.

In the hpt1 or fcy2 mutant strains, IMD-lacZ fusions were expressed at wild-type levels in the absence of guanine, whereas in the guk1 strain, IMD-lacZ fusions were 2-fold more expressed. We interpret this result as follows: whereas the hpt1 or fcy2 mutations affect only preformed purine utilization, the guk1 mutation affects both salvage and de novo GDP synthesis. Consequently, GDP levels might be more limiting in a guk1 mutant than in a hpt1 or fcy2 mutant strains. Consistently, a pur5 mutant, which is allelic to GUK1 (36), was previously shown to affect IMPDH activity (see the Discussion in Ref. 34).

MPA addition resulted in a 7-fold increase of IMD2 transcription, suggesting that blocking XMP synthesis severely depletes guanylic nucleotide supplies and consequently increases IMDs expression. Guanine addition overcomes this effect, since it allows guanine nucleotides supply through the salvage pathway. Accordingly, in the fcy2, hpt1, or guk1 mutant strains, guanine can no longer bypass MPA effect on the IMD genes.

Therefore, a decrease in guanine nucleotide pools (by MPA or the guk1 mutation) causes an increase in the expression of IMD genes, whereas an increase in these pools (by guanine addition) causes a decrease in IMD genes expression.

A similar negative regulation by guanylic nucleotide levels was reported in mammalian cells. Glesne and coworkers (43) have shown that MPA induced a 4-fold increase in the IMPDH mRNA level, whereas guanosine addition decreased it to 20% of the control levels. Moreover, these authors suggested that changes in the levels of guanine ribonucleotide pools, and not deoxyguanine nucleotide pools, are the primary determinant regulating IMPDH gene expression (43). Therefore, regulation of guanylic nucleotide synthesis appears strongly conserved between yeast and mammals.

The GRE cis-Negative Element of IMD2-- Mapping of the regulatory cis-elements present in the promoter of the IMD2 gene allowed us to identify a GRE, localized 308 to 301 pb upstream of the ATG start codon. Single substitutions of each of the GRE nucleotides to a C prevented guanine regulation of the IMD2 gene and led to an increased transcription of IMD2. Surprisingly, the GRE sequence, TATAAATA, is very similar to the TATA box consensus sequence. Moreover, the TATA-binding protein was shown to bind to the TATAAATA sequence in vitro, although with reduced affinity as compared with binding to the TATATAA consensus sequence (44). Nevertheless, since the GRE in IMD2 is a negative element, it is not expected to behave as a regular TATA box. Therefore, even if TATA-binding protein binds in vivo to the GRE sequence, it should have a different function than in the basal transcription initiation complex. Interestingly, the GRE sequence is also found in the IMD3 and IMD4 genes, at about 300 and 200 bp upstream from their respective ATGs, suggesting that IMD3 and IMD4 might also be regulated through a GRE cis-element. Mutations in the GRE sequence lead to an increased expression of IMD2 gene, suggesting that a repressor transcription factor could bind to the GRE box and repress IMD2 expression. Mutations in the TUP1 gene, encoding a corepressor involved in many different repression processes (45-48), did not affect guanine regulation of the IMD genes (data not shown). Also, electrophoretic mobility shift assays attempting to show binding of a trans-acting factor to a wild-type GRE, but not to a mutant GRE, were unsuccessful. This could be due to the low concentration of transcription factors in the crude extract used as a protein source.

In mammals, increased expression of IMPDH is observed in rapidly proliferating and deregulated cells, suggesting that in normal mammalian cells, IMPDH encoding genes are regulated by a repression mechanism. Moreover, it has recently been shown that in murine cells, p53 needs to repress IMPDH to exert its normal tumor suppression role (18). However, it is not yet known whether the p53 factor directly binds to human IMPDH-encoding genes. Even though S. cerevisiae does not have any p53 homolog, the overall regulation mechanisms could be conserved between yeast and mammals. Identification of this factor is now necessary to unravel the mechanisms by which IMD2 transcription is controlled.


    ACKNOWLEDGEMENTS

We are grateful to Drs. Fink and Watanabe for sending yeast strains. We thank Dr. Fernandes for suggestions on the manuscript.


    FOOTNOTES

* This work was supported by a fellowship from Fundação para a Ciência e Tecnologia (to M. E.-H.), by ARC Research Grant 5259, Conseil Régional d'Aquitaine, and CNRS UMR Grant 5095.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 33 5 56 99 90 55; Fax: 33 5 56 99 90 59; E-mail: B. Daignan-Fornier@ ibgc.u-bordeaux2.fr.

Published, JBC Papers in Press, October 16, 2000, DOI 10.1074/jbc.M007926200

2 V. Denis and B. Daignan-Fornier, unpublished results.


    ABBREVIATIONS

The abbreviations used are: IMPDH, IMP dehydrogenase; HU, hydroxyurea; MPA, mycophenolic acid; GRE, guanine response element; PCR, polymerase chain reaction; bp, base pair.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Daignan-Fornier, B., and Fink, G. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6746-6750[Abstract]
2. Denis, V., Boucherie, H., Monribot, C., and Daignan-Fornier, B. (1998) Mol. Microbiol. 30, 557-566[CrossRef][Medline] [Order article via Infotrieve]
3. Zimmermann, A. G., Gu, J. J., Laliberte, J., and Mitchell, B. S. (1998) Prog. Nucleic Acids Res. Mol. Biol. 61, 181-209[Medline] [Order article via Infotrieve]
4. Jackson, R. C., Weber, G., and Morris, H. P. (1975) Nature 256, 331-333[Medline] [Order article via Infotrieve]
5. Allison, A. C., Hovi, T., Watts, R. W., and Webster, A. D. (1975) Lancet 2, 1179-1183[CrossRef][Medline] [Order article via Infotrieve]
6. Nakamura, H., Natsumeda, Y., Nagai, M., Takahara, J., Irino, S., and Weber, G. (1992) Leuk. Res. 16, 561-564[Medline] [Order article via Infotrieve]
7. Nagai, M., Natsumeda, Y., Konno, Y., Hoffman, R., Irino, S., and Weber, G. (1991) Cancer Res. 51, 3886-3890[Abstract]
8. Nagai, M., Natsumeda, Y., and Weber, G. (1992) Cancer Res. 52, 258-261[Abstract]
9. Konno, Y., Natsumeda, Y., Nagai, M., Yamaji, Y., Ohno, S., Suzuki, K., and Weber, G. (1991) J. Biol. Chem. 266, 506-509[Abstract/Free Full Text]
10. Collart, F. R., Chubb, C. B., Mirkin, B. L., and Huberman, E. (1992) Cancer Res. 52, 5826-5828[Abstract]
11. Allison, A. C., and Eugui, E. M. (1994) Transplant. Proc. 26, 3205-3210[Medline] [Order article via Infotrieve]
12. Tricot, G. J., Jayaram, H. N., Lapis, E., Natsumeda, Y., Nichols, C. R., Kneebone, P., Heerema, N., Weber, G., and Hoffman, R. (1989) Cancer Res. 49, 3696-3701[Abstract]
13. Nelson, P. H., Eugui, E., Wang, C. C., and Allison, A. C. (1990) J. Med. Chem. 33, 833-838[Medline] [Order article via Infotrieve]
14. Sollinger, H. W. (1995) Kidney Int. 52 (suppl.), 14-17
15. Sollinger, H. W. (1995) Transplantation 60, 225-232[Medline] [Order article via Infotrieve]
16. Shaw, L. M., Sollinger, H. W., Halloran, P., Morris, R. E., Yatscoff, R. W., Ransom, J., Tsina, I., Keown, P., Holt, D. W., Lieberman, R., Jaklitsch, A., and Potter, J. (1995) Ther. Drug Monit. 17, 690-699[Medline] [Order article via Infotrieve]
17. Jain, A., Khanna, A., Molmenti, E. P., Rishi, N., and Fung, J. J. (1999) Surg. Clin. North Am. 79, 59-76[Medline] [Order article via Infotrieve]
18. Liu, Y., Bohn, S. A., and Sherley, J. L. (1998) Mol. Biol. Cell 9, 15-28[Abstract/Free Full Text]
19. Dujardin, G., Kermorgant, M., Slonimski, P. P., and Boucherie, H. (1994) Gene (Amst.) 139, 127-132[Medline] [Order article via Infotrieve]
20. Konrad, M. (1992) J. Biol. Chem. 267, 25652-25655[Abstract/Free Full Text]
21. Fukuchi, T., Nikawa, J., Kimura, N., and Watanabe, K. (1993) Gene (Amst.) 129, 141-146[CrossRef][Medline] [Order article via Infotrieve]
22. Collart, F. R., and Huberman, E. (1990) Blood 75, 570-576[Abstract]
23. Gilbert, H. J., Lowe, C. R., and Drabble, W. T. (1979) Biochem. J. 183, 481-494[Medline] [Order article via Infotrieve]
24. Kanzaki, N., and Miyagawa, K. (1990) Nucleic Acids Res. 18, 6710[Medline] [Order article via Infotrieve]
25. Natsumeda, Y., Ohno, S., Kawasaki, H., Konno, Y., Weber, G., and Suzuki, K. (1990) J. Biol. Chem. 265, 5292-5295[Abstract/Free Full Text]
26. Sifri, C. D., Wilson, K., Smolik, S., Forte, M., and Ullman, B. (1994) Biochim. Biophys. Acta 1217, 103-106[Medline] [Order article via Infotrieve]
27. Tiedeman, A. A., and Smith, J. M. (1991) Gene (Amst.) 97, 289-293[Medline] [Order article via Infotrieve]
28. Okada, M., Shimura, K., Shiraki, H., and Nakagawa, H. (1983) J. Biochem. (Tokyo) 94, 1605-1613[Abstract]
29. Ikegami, T., Natsumeda, Y., and Weber, G. (1987) Life Sci. 40, 2277-2282[CrossRef][Medline] [Order article via Infotrieve]
30. Holmes, E. W., Pehlke, D. M., and Kelley, W. N. (1974) Biochim. Biophys. Acta 364, 209-217[Medline] [Order article via Infotrieve]
31. Myers, A. M., Tzagoloff, A., Kinney, D. M., and Lusty, C. J. (1986) Gene (Amst.) 45, 299-310[CrossRef][Medline] [Order article via Infotrieve]
32. Kippert, F. (1995) FEMS Microbiol. Lett. 128, 201-206[CrossRef][Medline] [Order article via Infotrieve]
33. Barton, A. B., Bussey, H., Storms, R. K., and Kaback, D. B. (1997) Yeast 13, 1251-1263[CrossRef][Medline] [Order article via Infotrieve]
34. Woods, R. A., Roberts, D. G., Friedman, T., Jolly, D., and Filpula, D. (1983) Mol. Gen. Genet. 191, 407-412[Medline] [Order article via Infotrieve]
35. Guetsova, M. L., Lecoq, K., and Daignan-Fornier, B. (1997) Genetics 147, 383-397[Abstract/Free Full Text]
36. Lecoq, K., Konrad, M., and Daignan-Fornier, B. (2000) Genetics 156, 953-961[Abstract/Free Full Text]
37. Vitols, E., Bauer, V. A., and Stanbrough, E. C. (1970) Biochem. Biophys. Res. Commun. 41, 71-77[Medline] [Order article via Infotrieve]
38. Elford, H. L. (1968) Biochem. Biophys. Res. Commun. 33, 129-135[Medline] [Order article via Infotrieve]
39. Meng, L. M., and Nygaard, P. (1990) Mol. Microbiol. 4, 2187-2192[Medline] [Order article via Infotrieve]
40. Meng, L. M., Kilstrup, M., and Nygaard, P. (1990) Eur. J. Biochem. 187, 373-379[Abstract]
41. Weng, M., Nagy, P. L., and Zalkin, H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7455-7459[Abstract]
42. Ebbole, D. J., and Zalkin, H. (1987) J. Biol. Chem. 262, 8274-8287[Abstract/Free Full Text]
43. Glesne, D. A., Collart, F. R., and Huberman, E. (1991) Mol. Cell. Biol. 11, 5417-5425[Medline] [Order article via Infotrieve]
44. Wong, J. M., and Bateman, E. (1994) Nucleic Acids Res. 22, 1890-1896[Abstract]
45. Keleher, C. A., Redd, M. J., Schultz, J., Carlson, M., and Johnson, A. D. (1992) Cell 68, 709-719[Medline] [Order article via Infotrieve]
46. Mukai, Y., Harashima, S., and Oshima, Y. (1991) Mol. Cell. Biol. 11, 3773-3779[Medline] [Order article via Infotrieve]
47. Zhang, M., Rosenblum-Vos, L. S., Lowry, C. V., Boakye, K. A., and Zitomer, R. S. (1991) Gene (Amst.) 97, 153-161[CrossRef][Medline] [Order article via Infotrieve]
48. Williams, F. E., and Trumbly, R. J. (1990) Mol. Cell. Biol. 10, 6500-6511[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.